Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Tempus presented ESMO 2026 data showing its AI-enabled pre-screening panel achieved greater than 80% sensitivity across all 12 biomarkers in advanced NSCLC, exceeding 90% for several. The multi-center analysis covered 60,459 cases across 56,969 patients, using routine H&E pathology images to predict biomarker status and prioritize confirmatory testing, in collaboration with Pfizer.
Key figures
- Patients
- 56969
- Sensitivity
- >80% across all 12 biomarkers, >90% for several
- Cases analyzed
- 60459
- Biomarkers assessed
- 12
- Paige predict biomarkers
- 123
- Preview turnaround hours
- 24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.